Kymera Therapeutics (KYMR) PT Raised to $97 at Brookline Capital Markets
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts KYMR Hot Sheet
Price: $127.09 --0%
Rating Summary:
26 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 11 | New: 7
Rating Summary:
26 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 11 | New: 7
Join SI Premium – FREE
Brookline Capital Markets analyst Leah Rush Cann raised the price target on Kymera Therapeutics (NASDAQ: KYMR) to $97.00 (from $90.00) while maintaining a Buy rating.
You May Also Be Interested In
- Kymera Therapeutics (KYMR) PT Raised to $170 at Barclays
- Neutron Holdings (LIME) PT Lowered to $27 at Citizens on Lowered Profitability Expectations
- Keurig Dr Pepper (KDP) PT Raised to $40 at Wells Fargo
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
